Creo Medical (AIM: CREO)

Currency in GBP

Last close As at 09/06/2023


2.00 (8.60%)

Market capitalisation


UK-based Creo Medical focuses on the development and commercialisation of minimally invasive electrosurgical devices. Its six products in the flagship CROMA platform have all been CE marked, with five cleared by the FDA. Acquired in 2020, Albyn Medical provides Creo with profitable products and a direct salesforce in Europe.

Creo’s products are in a large and lucrative market. Conmed estimates the gastrointestinal endoscopic technologies market is worth c $3.0–3.2bn and the radio frequency energy based surgical device market is $2.7–2.9bn pa. Entering the robotics and laparoscopic markets further increases the scale of opportunity open to Creo.




Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Craig Gulliford


  • David Woods

    Chief commercial officer

  • Rhys Davies

    Communications manager

  • Richard Rees


Balance Sheet

Forecast net cash (£m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 2.0 2.0 (72.8)
Relative 4.3 6.4 (72.5)
52 week high/low 96.5p/18.4p


Creo Medical has announced that its flagship product, Speedboat Inject, has been selected for assessment by the National Institute for Health and Care Excellence (NICE), a UK-based independent expert organisation that provides national guidance on medical practices and technologies. Post selection, the device will go through a committee review of the headline data and a multi-stage evaluation process by NICE, to investigate Speedboat for endoscopic submucosal dissection of lower gastrointestinal lesions. While Creo’s Pioneer training programme and robotics deals with Intuitive Surgical and CMR Surgical hold significant potential for Speedboat’s uptake globally, the NICE guidance, if favourable, would likely support increased adoption of the device in the UK, providing further validation for the product as well as the CROMA platform.

Y/E Dec Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2021A 25.2 (20.0) (29.7) (14.58) N/A N/A
2022A 27.2 (20.8) (31.0) (14.85) N/A N/A
2023E 32.8 (20.7) (24.3) (6.26) N/A N/A
2024E 40.8 (11.5) (14.8) (3.59) N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free